LeonaBio (LONA): Can the Stock Recover to the $15 Analyst Target?
Key Takeaways
- The selected stock price target is $15, the floor of a $15–$20 analyst range that implies a gain of more than 360% from recent prices near $3.25.
- The strongest bullish catalyst is lasofoxifene, a Phase 3 drug candidate for treatment-resistant metastatic breast cancer, with topline data expected in the second half of 2027.
- The biggest risks are the absence of revenue, a binary clinical-trial outcome, heavy share dilution, and extreme price volatility.
- Key levels include the 52-week low near $3.15 as support and a prior resistance zone around $5 to $6, with the 52-week high of $14.21 as the major ceiling.
- Reaching $15 is plausible only if the Phase 3 readout is positive; without that catalyst, the move appears difficult to justify.
Why the $15 Level Matters
After the January 2026 rebranding from Athira Pharma to LONA, the company shifted focus to oncology. In December 2025 it obtained an exclusive global license for lasofoxifene, a selective estrogen receptor modulator, from Sermonix Pharmaceuticals. The compound is now in the registrational ELAINE-3 Phase 3 trial, evaluating lasofoxifene plus abemaciclib in estrogen-receptor-positive, HER2-negative, ESR1-mutated metastatic breast cancer. This genetically defined population has limited options after standard endocrine therapy, and analysts view it as a potential multi-billion-dollar opportunity. That context helps explain why the conservative $15 sell-side target has become a key reference point for investors considering a recovery path. I also checked this using AI Daily Buy/Sell Signals to see how recent price action compares with similar names.
Current Market Position
In late September 2026, LONA shares traded near $3.25, giving the company a market capitalization of roughly $30 million. That marks a steep decline from the 52-week high of $14.21 reached in March 2026 and leaves the stock just above its 52-week low near $3.15. The company remains pre-revenue with a trailing-twelve-month net loss and a beta close to 2.0, reflecting elevated volatility. On the balance sheet, roughly $51 million in cash is expected to support operations into 2028.
Potential Catalysts Ahead
The main driver remains the ELAINE-3 trial. Enrollment passed the 500-patient mark in August 2026, with full enrollment targeted for the fourth quarter of 2026 and topline data due in the second half of 2027. A positive outcome could position LONA as a standard-of-care option in ESR1-mutated breast cancer and support a meaningful re-rating. Secondary programs include ATH-1105, an oral HGF/MET modulator for ALS and other neurodegenerative diseases that has completed Phase 1 in healthy volunteers, with a Phase 2 ALS study expected to begin dosing. The December 2025 $90 million private placement, co-led by Commodore Capital, Perceptive Advisors, and TCGX, also extends the cash runway and lowers near-term financing risk.
Key Risks to Monitor
As a pre-revenue biotech, LONA lacks earnings or sales to support valuation, so a negative or inconclusive Phase 3 result could sharply reduce market value. Dilution is another factor: shares outstanding increased more than 230% year over year due to repeated financings. Technically, the stock must first reclaim the $5–$6 zone that served as prior support before any sustained move toward double digits looks credible. The sharp single-session drop that took shares near $3.15 also highlights how quickly sentiment can reverse.
Analyst Views and Price Targets
Four analysts tracked by S&P Global maintain a consensus “Buy” rating on LONA, with an average target of $17.33 and a range of $15 to $20. Mizuho holds a Buy rating and $15 target, Piper Sandler initiated with Overweight and a $20 target, and Citizens JMP carries a target near $17. These projections reflect optimism about the lasofoxifene opportunity but remain conditional on clinical success.
Technical Levels Worth Watching
The 52-week low near $3.15 represents critical support; a decisive break below it would point to further downside. On the upside, the first notable resistance lies in the $5–$6 area. The $14.21 prior high remains the major hurdle, and the $15 target sits just above that level, meaning the stock would need to surpass previous highs to reach the objective.
Final Assessment
Can LONA reach $15? The data indicate it is possible, but only if specific conditions are met. The most constructive elements are a well-defined Phase 3 program with large-market potential, data expected in 2027, and funding into 2028. The main risks remain equally clear: no current revenue, binary clinical results, ongoing dilution, and a stock that has already retraced nearly all of its 2026 gains. Investors should track enrollment-completion updates, any progress on the ATH-1105 ALS program, cash position versus burn rate, and—most importantly—the ELAINE-3 topline readout. Until that data arrives, the path to $15 depends more on clinical execution than on market momentum alone.
Monitoring Volatile Names with AI Tools
In my own research on names like LONA, I find AI Daily Buy/Sell Signals helpful for tracking shifts in technical behavior across thousands of stocks and ETFs. The platform generates automated Buy, Sell, or Hold signals that can highlight emerging trends or changes in momentum without requiring constant manual chart review. It serves as one more data point alongside clinical updates and analyst targets.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
LONA in upward trend: price expected to rise as it breaks its lower Bollinger Band on September 24, 2026
LONA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 43 of 46 cases where LONA's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where LONA's RSI Indicator exited the oversold zone, 25 of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 54 of 64 cases where LONA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
Following a +35.01% 3-day Advance, the price is estimated to grow further. Considering data from situations where LONA advanced for three days, in 221 of 266 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on LONA as a result. In 70 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
The Moving Average Convergence Divergence Histogram (MACD) for LONA turned negative on September 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 39 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
LONA moved below its 50-day moving average on September 09, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for LONA moved below the 200-day moving average on September 21, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LONA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for LONA entered a downward trend on October 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 11 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.805) is normal, around the industry mean (26.780). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. LONA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LONA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement